(KYTH) (KYTH) Stock Price, News & Analysis

Company Overview

KYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.09 to $0.09
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KYTH Stock Analysis - Frequently Asked Questions

How were (KYTH)'s earnings last quarter?

(KYTH) (NASDAQ:KYTH) released its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, missing analysts' consensus estimates of ($1.10) by $0.34. The biopharmaceutical company had revenue of $288 million for the quarter.

What other stocks do shareholders of (KYTH) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (KYTH) investors own include Revance Therapeutics (RVNC), Bausch Health Cos (BHC), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), NPS Pharmaceuticals (NPSP), (RPTP) (RPTP) and Splunk (SPLK).

Company Calendar

• Last Earnings: 8/06/2015
• Today: 6/21/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KYTH
• CIK: 1436304
• Web: N/A
• Phone: +1-818-5874500
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A